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ABSTRACT 
Excessive daytime sleepiness (EDS) is one of the earliest and most common non-motor 
symptoms of PD, substantially impacting on patient’s quality of life. Using the Parkinson's 
Progression Markers Initiative database, we performed a case-control study to investigate 
whether dopaminergic deficit is associated with the development of EDS using dopaminergic 
specific single photon emission computed tomography (SPECT) molecular imaging of 
dopamine transporters (DAT). We enrolled 84 early de novo PD patients with EDS and 84 
without EDS, who were matched for age, gender, age of diagnosis, years of education and 
disease duration. We assessed and compared semi-quantified [123I]FP-CIT SPECT, and motor 
and non-motor features amongst these two groups, alongside exploring the clinical and 
imaging correlates of EDS and the predictive significance of these markers in the 
development of EDS. PD patients with EDS had worse non-motor (MDS-UPDRS Part-I, 
P<0.001) and motor (MDS-UPRDS Part-II, P=0.005) experiences of daily living, as well as 
worse autonomic (SCOPA-AUT, P<0.0001) and cognitive (MoCA P=0.05) function, 
depression (GDS, P=0.002), and reduced caudate DAT ([123I]FP-CIT, P=0.024) compared to 
PD patients without EDS. Lower caudate [123I]FP-CIT values correlated with higher EDS 
scores (r=-0.192, P=0.013). Among patients without EDS, 47 PD patients (56%) developed 
EDS over a median follow-up of 36 months. Cox multivariate analysis including all clinical 
and imaging data available, revealed that abnormal caudate [123I]FP-CIT uptake (P=0.030) 
and disease duration (P=0.018) were predictors for the development of EDS. Although our 
findings indicate that dopaminergic deficits in the caudate may be associated to EDS in 
patients with PD, the pathophysiological causality is debateable, given that dopamine caudate 
denervation may covary with non-dopaminergic involvement at other targets and with non-
dopaminergic involvement.  
 
Keywords: Excessive daytime sleepiness; [123I]FP-CIT; Parkinson; Caudate.  
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1.0 INTRODUCTION 
Excessive daytime sleepiness (EDS) is one of the most common and troublesome non-motor 
symptoms (NMS) in both early and advanced Parkinson’s disease (PD) [1]. Although a range 
of NMS are primarily reported to be associated with non-dopaminergic deficits, such as 
depression [2], BMI changes [3] and fatigue [4], the dopaminergic system has also been 
identified as a pivotal contributor to non-motor symptoms in PD [5], reflecting the 
multisystem nature of the disorder. Politis and colleagues reported in vivo evidence of 
dopamine dysfunction in the hypothalamus of PD patients, suggesting a dopaminergic 
contribution to several non-motor symptoms, including sleep disorders, neuro-endocrinal 
problems and autonomic dysfunction [6]. NMS are often poorly identified and inadequately 
treated, highlighting the challenge attached with NMS management. Therefore, gaining an 
insight into the neurobiological mechanisms underlying these symptoms could improve 
management and the development of novel treatments.  
The clinical heterogeneity of PD has led to the discovery of phenotypic subtypes of motor 
and non-motor symptoms [7]. Patients with daytime sleepiness, along with cognitive 
impairment, autonomic dysfunction and depression were recognised as a specific subtype of 
PD [7], instigating an interest in the clinical associations of EDS, alongside phenotypic and 
neurobiological risk factors of EDS development.  
An amalgamation of dopaminergic denervation, nocturnal sleep disruption and dopaminergic 
medication is likely to be causative [8, 9], though several studies have suggested that EDS 
may be a primary feature of PD, unrelated to dopaminergic therapies or nocturnal sleep 
disturbances [10]. A magnetic resonance imaging (MRI) brain morphometry revealed that 
EDS in PD patients was related to atrophy of the medial cerebellar peduncle, suggesting that 
degeneration of the pontomedullary respiratory centres may underlie EDS development in PD 
[11]. Further, patients experiencing daytime sleepiness demonstrated a prominent impairment 
in circadian melatonin secretion, suggesting that circadian dysfunction may underlie 
excessive sleepiness [12]. A genetic component contributing to the pathogenesis of EDS has 
also been reported [13]. Furthermore, Saper and colleagues proposed that a ‘flip-flop switch’ 
is responsible for the sleep-wake cycle in primates, whereby the suprachiasmatic nucleus 
regulates the internal rhythm between two switches, with hypocretin potentially playing a 
regulatory role [14]. The quantity of hypocretin-producing neurons and the CSF level of 
hypocretin-1 have been shown to be reduced in PD [15-17], with consistent loss of 
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hypocretin-producing neurons demonstrated by a reduction in the number of post-mortem 
hypothalamic hypocretin neurons, acknowledged as the ‘gold standard’ [16, 17].  
Disease variables found to be associated with EDS include longer disease duration, older age, 
severity of motor manifestations, depression, cognitive impairment and, non-tremor dominant 
motor phenotype [8, 18], though not all epidemiological studies of PD have discovered the 
same picture or disease variables to be associated with EDS [19]. 
Studies investigating EDS and dopaminergic pathways discovered that subjective daytime 
sleepiness is associated with striatonigral degeneration [20], though others have proposed that 
it may be associated with extrastriatal dopaminergic loss in specific brain structures involved 
in alertness [21]. Thus, the role of the striatum in the development of EDS remains unclear.   
We aimed to explore the relationship between EDS and striatal dopamine terminals, using 
[123I]FP-CIT single photon emission computed tomography (SPECT), alongside determining 
the clinical correlates and risk factors in the development of EDS, in de novo (drug-naïve) PD 
patients. We hypothesised that EDS would be associated with striatal dopaminergic 
denervation. 
 
2.0 METHODS 
The Parkinson’s Progression Markers Initiative (PPMI) is a five-year observational, 
international, multi-centre study designed to provide insight into disease aetiology by 
identifying PD progression biomarkers. The present study was written according to the 
STROBE guidelines. This study is registered with ClinicalTrials.gov, number NCT01141023. 
 
2.1 Cohort selection 
We included PD patients aged >30 years old, who had a disease duration ≤ 2 years and were 
not on dopamine replacement therapy. Institutional review boards approved the study and 
written informed consent was obtained from all participants. From a total of 412 patients with 
PD, 84 had EDS according to the Movement Disorder Society Unified PD Rating Scale 
(MDS-UPDRS) Part-I, item 1.8 ‘daytime sleepiness’. This self-reported, self-completed 
instrument consists of 5 statements, rating from 0: normal to 4: severe, with a higher rating 
corresponding to a higher degree of EDS. The presence of EDS was defined as daytime 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
sleepiness interfering with daily activities and social interactions (cut-off >1). All clinical and 
imaging assessments were performed in subjects who were not receiving any dopaminergic 
medication, at baseline. The cut-off values considered abnormal for all clinical and imaging 
variables were calculated as 2 S.D. from the mean of HCs, as previously stated [22].  
Using propensity scores, PD patients with EDS were matched 1:1 for age, gender, age at 
disease diagnosis, duration of disease and years of education with 84 PD patients without 
EDS. Characteristics of patients included are summarised in Table 1.  
 
2.2 Dopaminergic imaging 
SPECT images were obtained 4 ± 0.5 h after administrating an injection of approximately 
185 MBq [123I]FP-CIT. [123I]FP-CIT SPECT scans were analysed following the imaging 
technical operations manual (http://ppmi-info.org/). In brief, SPECT image volumes were 
spatially normalised to an Ioflupane template. The eight most prominent axial slices 
containing the striatum were summed and a standardised volume of interest (VOI) template 
was then applied to this image. VOI analyses were performed on the right and left caudate 
and putamen, employing the occipital region as the reference tissue. Specific binding ratios 
(SBR) were calculated as the ratio of the putamen or caudate VOI count density divided by 
the occipital cortex count density minus one. This measure approximates the binding 
potential, BPnd, when the radioligand is in equilibrium at the target site and has previously 
been reported with Ioflupane SPECT [23].  
2.3 Structural imaging  
T1-weighted Magnetic Resonance Imaging (MRI) scans were acquired in the saital plane on 
3T Siemens (TIM Trio and Verio) scanners (Erlangen, Germany), employing a 
magnetisation-prepared rapid-acquisition gradient echo sequence. The parameters of the MRI 
sequence were as follows: repetition time: 2,300/1,900 milliseconds; echo time: 
2.98/2.96/2.27/2.48/2.52 milliseconds; inversion time: 900 milliseconds; flip angle: 9°; 
matrix: 256 × 256; and 1mm3 isotropic voxel.  
Surface-based analysis was carried out using the freely available software package FreeSurfer 
(version 5.3, http://surfer.nmr.mgh.harvard.edu). In brief, the FreeSurfer preprocessing 
pipeline includes (1) removal of non-brain tissue; (2) automated Talairach transformation; (3) 
segmentation of subcortical white matter and deep grey matter structures (4) intensity 
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normalisation (5) tessekkation of the gray matter/white matter boundary; (6) automated 
topology correction; (7) surface deformation; and (8) registration of the subjects’ brains to the 
common spherical atlas. The results implemented in FreeSurfer were visually inspected and 
manually edited, if required.  
Regions-of- interest (ROIs) included subcortical structures such as caudate, putamen, 
accumbens, pallidum, thalamus, hippocampus and amygdala, as well as cortical structures 
such as precentral and postcentral gyrus, anterior and posterior cingulate, entorhinal cortex, 
fusiform gyrus, inferior and superior parietal cortex, inferior, middle and superior frontal 
cortex, insula cortex, parahippocampal cortex, inferior, middle and superior temporal cortex, 
lateral occipital and lateral orbitofrontal cortex.        
2.4 Assessment of outcomes and follow-up 
PD patients attended a follow-up visit once every year, where the physician reviewed the 
patient’s condition. This included reassessing the patient for EDS development. Follow-up 
period was terminated either at the patient’s last visit or if the patient developed EDS.  
 
2.5 Dopaminergic therapy 
Study participants could start dopamine replacement therapy (DRT) at any point after 
baseline as part of routine clinical care. A participant was considered to have received DRT 
(dopamine agonists, levodopa, monoamine oxidase type B (MAO-B) inhibitors) from the first 
time it was recorded at an annual study visit.  Information about medication dosages was not 
readily ascertained in the database and is not included. 
 
2.6 Statistical methods 
Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS), 
version 22 and graphical illustration in GraphPad Prism 6. For all variables, Gaussianity was 
tested with Kolmogorov-Smirnov test. Multivariate analysis of variance (MANOVA) was 
used to assess the main effects of all clinical and imaging variables between the group of PD 
patients with EDS and PD patients without EDS. If the overall multivariate test was 
significant, P values for each variable were calculated following Bonferroni correction. 
Categorical variables were compared using a χ2 test. A one-way ANOVA and Dunnett’s 
post-hoc test was carried out to determine differences between the means of the three groups 
(patients who scored 0, 1 or 2 on UPDRS-Part 1, Item 1.8). Cohen’s d was calculated for 
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each variable by dividing the mean difference by the pooled standard deviation. Pearson and 
Spearman's correlation tests were carried out to assess the relationship between [123I]FP-CIT 
SPECT and EDS. To determine the independent predictors of EDS, multivariate Cox 
proportional hazards analyses (backward conditional) were used including variables 
achieving P<0.10 on univariate analysis. Only the time to occurrence of the first event in a 
category for a given subject was used. To increase the stability of our findings, we confirm 
that the outcome present at one visit was still present at subsequent visits. Statistical 
significance was set at P<0.05, Bonferroni corrected. 
 
3.0 RESULTS 
3.1 Dopaminergic imaging 
Caudate [123I]FP-CIT binding was reduced in PD patients with EDS compared to PD patients 
without EDS (1.87±0.54 vs 2.06±0.53, P=0.025; Figure 1 and 2A). Caudate [123I]FP-CIT 
uptake did not correlate with insomnia (MDS-UPDRS, Part 1, item 1.7, P=0.288, ρ=0.052) or 
RBD (RBDSQ, P=0.091, ρ=-0.082). Putamen [123I]FP-CIT binding was not significantly 
different between the two groups (0.77 ±0.30 vs 0.83 ±0.27, P=0.164). 
 
3.2 Structural imaging 
There were no differences in cortical thickness or subcortical volumes between PD patients 
with EDS compared to those without (P>0.1).  
 
3.3 Clinical phenotype analysis 
PD patients with EDS had an overall worse clinical picture (MDS-UPDRS Total, P<0.001), 
worse non-motor (MDS-UPDRS Part-I (excluding item 1.8 subscores), P<0.001) and motor 
experiences of daily living (MDS-UPRDS Part-II, P=0.001), as well as worse autonomic 
(SCOPA-AUT, P<0.001) cognitive (MoCA, P=0.01) and depression (GDS, P=0.002) scores 
compared to PD patients without EDS (Table 1; Figure 2A). No differences were found in 
motor symptom severity between PD with and without EDS (MDS-UPRDS Part-III, P>0.10).  
  
3.4 Correlations  
Higher EDS scores at baseline were associated with decreased caudate [123I]FP-CIT binding 
(r=-0.192; P=0.013), global non motor symptom burden (MDS-UPDRS Part-I, ρ=0.470;  
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P<0.001), worse motor experiences of daily living (MDS-UPDRS Part-II, ρ=0.349; P<0.001), 
autonomic dysfunction (SCOPA-AUT, ρ=0.366; P>0.001), cognitive impairment (MoCA, ρ=-
0.175; P=0.023) and depression (GDS, ρ=0.264; P=0.002) (Figure 2B) at baseline.  
 
3.5 EDS predictive analysis 
Of the 84 PD patients without EDS at baseline, 34 initiated levodopa treatment (40.5%) and 
27 started treatment with dopamine agonist (32.1%). 47 PD patients (56%) developed EDS 
over a mean follow-up of 36.9 ± 20.2 months (range: 3–60 months). Of these 47 PD patients, 
23 (48.9%) were taking levodopa and 15 (31.9%) were taking dopamine agonists. Of the 37 
PD patients who did not develop EDS, 11 (29.7%) were taking levodopa and 12 (32.4%) 
were taking dopamine agonist. There was no significant difference in dopamine agonist 
treatment between those PD patients who go onto develop EDS compared to those who do 
not go onto develop EDS (P=0.397). 
 
Multivariate Cox proportional hazards regression analysis, performed including all variables 
with P≤0.10 at univariate analysis, revealed that baseline abnormal (≤1.76) caudate [123I]FP-
CIT (Hazard ratio [HR]=1.94 Confidence Interval [CI]=1.06–3.53, P=0.030; Figure 3) and 
disease duration (HR=1.62, [CI]=1.08–2.41 per year of disease, P=0.018) were predictors for 
developing EDS. Levodopa (HR=1.441, CI=0.808-2.572, P>0.1) and dopamine agonists 
(HR=0.657, CI=0.354-1.220, P>0.1) were not predictors for developing EDS.  
 
4.0 DISCUSSION 
 
Our findings demonstrate that the development of EDS in patients with PD is related to the 
advancing disease, reflected particularly by non-motor symptom burden, and dopaminergic 
deficits in the caudate, with no differences in brain atrophy. We have combined [123I]FP-CIT-
SPECT and MR-based structural imaging  and have showed a loss of dopaminergic function 
in the caudate of PD patients with EDS compared to those without. Dopaminergic deficits in 
the caudate were associated with the severity of EDS in the PD-EDS group and with a two-
fold increased risk (HR=1.94) of developing EDS over a period of 36 months in the PD non-
EDS group. Our findings are in line with a previous smaller cross-sectional study which has 
reported correlations between striatal dopamine transporter (DAT) loss and sleep problems in 
patients with PD [20]. DAT regulates dopamine concentration within the synaptic cleft via 
the reuptake of dopamine into presynaptic neurons. SPECT radiotracers for the DAT provide 
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excellent markers for the integrity of the presynaptic dopaminergic system. ‘Loss of function’ 
refers to DAT loss, which is either the result of loss of dopaminergic terminals or a change in 
synaptic dopamine levels. 
 
Although the correlations between EDS and cognitive impairment, autonomic dysfunction 
and depression were somewhat weak, likely due to the sample size of the cohort, they were 
found to be associated, particularly when comparing the PD-EDS and PD non-EDS cohorts. 
This is consistent with previous studies which have revealed patterns of coherency amidst 
motor and non-motor domains within PD. van Rooden et al. [24] discovered that daytime 
sleepiness was often present with depression, cognitive impairment, autonomic dysfunction 
and psychotic and axial symptoms, with a second pattern characterised by sleep disturbances, 
depression and cognitive impairment, highlighting a conspicuous disease profile implicated 
with sleep. EDS has also been found to be an independent predictive factor for cognitive 
difficulties in the general elderly population [25], suggesting EDS is a significant risk factor 
for cognitive deficits. Intriguingly, the caudate dopaminergic function has been recognised as 
a fundamental node in supporting cognitive domains. Previous findings have illustrated that 
loss of dopaminergic projections to the caudate correlate with degree of dementia in PD [26], 
alongside others reporting that a reduction in caudate uptake of [18F]DOPA is associated with 
verbal and visual memory functioning, verbal fluency and, delayed recall [27] highlighting 
that the functional integrity of presynaptic dopaminergic synthesis is crucial for cognitive 
function in PD. More recently, in a PPMI study, Schrag and colleagues demonstrated that 
dopaminergic denervation within the caudate, alongside four other variables, predicted 
cognitive impairment at 2 years [28]. This is particularly interesting given that Schrag 
explored a larger version of, essentially, the same cohort and reported similar findings. 
Therefore, the mechanisms underlying the development of EDS and cognitive problems may 
share an overlapping dopaminergic substrate. Therefore, the mechanisms underlying the 
development of EDS and cognitive problems may share an overlapping dopaminergic 
substrate.  
 
Dopamine has been reported to promote wakefulness in a range of animal models including 
cats and drosophila [29, 30], though studies have also demonstrated its association with 
sleepiness and the sleep state [31]. This discrepancy can be explained by dopamine mediating 
both wakefulness and sleepiness depending on its concentration. Studies have, for example, 
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demonstrated that either excessive or insufficient dopamine impairs cognitive functions [32], 
suggesting that a similar mechanism may underlie the varying sleep disorders in PD, 
particularly because discrete classes of receptors may be activated by varying concentrations 
of dopamine based on receptor affinity [9].  
 
The caudate nucleus is a major receptive component of the basal ganglia, embedded within 
its large neural network. The striatum is the focal output structure, receiving afferent fibres 
from distinct cortical areas, projecting them on to the thalamus and brainstem for auxiliary 
propagation via pallidum back to cortex [33]. Distinct functional zones have been proposed, 
within the caudate, based on their innervation by specific cortical areas [33]. It is not 
surprising that the caudate has surfaced as a common node in the regulatory systems involved 
in sleep problems, arousal and executive function, due to its complex role in regulating the 
impact of impulses between the thalamus and cortex. Hyper-arousal indices have emerged in 
studies that have specifically disrupted caudate function, highlighting that caudate lesions 
might induce hyper-responsivity and behavioural restlessness [30].  
Recent studies have implicated the basal ganglia and its respective structures in arousal and 
the sleep-wake cycle.  Neurotoxic lesion studies have demonstrated the pivotal role of the 
basal ganglia in regulating the sleep-wake cycle. Specifically, bilateral striatal lesions result 
in reduced wakefulness, which is attenuated when the striatal (caudoputamen) lesions include 
the nucleus accumbens [34]. These findings highlight that the caudate is involved in 
promoting wakefulness whereas the nucleus accumbens primarily enhances sleepiness. In this 
direction, our results highlight that a loss of DAT, therefore dopamine, within the caudate, 
could in fact cause sleepiness in PD patients. However, it is also important to recognise the 
role of other major nuclei including the globus pallidus, thalamus and substantia nigra. Cell 
body-specific lesioning of the globus pallidus externa has resulted in insomnia, with rats 
demonstrating a prominent increase of up to 45% [34]. Further, neuronal loss within the 
substantia nigra, excluding the globus pallidus, consequently affected sleep-wake behaviour, 
specifically presenting as an increase of wakefulness [34, 35]. Lazarus and colleagues 
propose that the nucleus accumbens, in particular, is a key node in the circuitry for sleep [36]. 
A2A receptors residing in the nucleus accumbens are fundamental for the wakefulness 
induced by caffeine, and presumably modulate neural substrates through which arousal is 
also produced by dopamine. The nucleus accumbens encompasses GABAergic projections to 
an array of targets, including the ventral tegmental area (VTA), ventral pallidum, 
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parabrachial nucleus and lateral hypothalamus, which are recognised to contribute to arousal 
[36].  
The dopaminergic system has been acknowledged to play key role in promoting wakefulness 
as demonstrated by several studies. Eban-Rothschild and colleagues revealed the role of VTA 
dopaminergic neurons in maintaining the awake state, by recording calcium activity in mice 
[37]. They found that optogenetic stimulation of VTA dopaminergic neurons initiated and 
maintained wakefulness, whereas inhibition promoted sleepiness. Lu and colleagues, on the 
other hand, reported that tyrosine hydroxylase immunoreactive dopaminergic cells within the 
ventral periaqueductal gray matter (vPAG) express Fos protein during wakefulness, but none 
during sleep, with destruction of these cells leading to increased total daily sleep [38]. Cho et 
al (2017) demonstrated the role of dopaminergic neurons of the dorsal raphe nucleus in 
modulating the sleep-wake pattern [39]. They found dorsal raphe nucleus dopaminergic 
activity fluctuates across sleep-wake states, with activity being highest at wakefulness, as 
well as optogenetic activation promoting wakefulness and chemogenetic inhibition opposing 
wakefulness. These results demonstrate the relevance of dopaminergic structures and their 
forebrain targets in regulating sleep-related behaviours, as well as emphasising the 
multifaceted nature of sleep, which involves multiple neural systems.  
Studies have also demonstrated that modafinil, which is commonly used to treat daytime 
sleepiness in PD, works by enhancing extracellular levels of dopamine within the nucleus 
accumbens and medial prefrontal cortex [40] The arousal-inducing effects of modafinil is 
abolished in mice following DAT knockout [41] thus implicating the loss of DAT in the 
pathophysiology of daytime sleepiness, potentially through a loss of dopamine clearance 
from the synapses. Qu and colleagues demonstrated that the arousal effects of modafinil is 
exclusively mediated via both D1 and D2 receptors, with D2 receptors being of particular 
significance [42].  
It is also important to consider that a dopamine caudate denervation could covariate with non-
dopaminergic involvement, resulting in daytime sleepiness. The Braak hypothesis proposes 
that synuclein pathology initially appears in the lower brainstem, where arousal centres 
reside. The varying degrees of synuclein pathology depict a temporal sequence of events, 
suggesting that even after the clinical manifestation of PD transpires, neuronal loss of non-
dopaminergic systems may underlie EDS. The remaining dopaminergic innervation within 
the head of the caudate may merely pose as a marker for other, less visible sites on [123I]FP-
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CIT SPECT. For example, the brainstem, with specific regard to the pontine tegmentum, 
plays a fundamental role in regulating sleep, via centrally regulating the pace for sleep-related 
activity throughout the brain. Hypothalamic changes, in particular, have been associated with 
dopaminergic pathology by using PET imaging [43], which has greater resolution for small 
areas. These changes are likely to play a key role the development of EDS, given the 
established role of hypothalamic neuropeptides, hypocretins (orexins), in regulating sleep and 
arousal states [16, 17, 44]. Further, we found that higher EDS scores were associated with 
higher global non-motor symptoms burden, worse motor experiences of daily living, 
autonomic dysfunction, cognitive impairment and depression. The lower caudate uptake in 
our cohort of PD patients with EDS could, therefore, be reflecting a more severe disease that 
has already spread to the caudate nuclei, which in turn could be associated with the increased 
severity of non-motor symptoms, including EDS. In this direction, EDS may have no direct 
link with dopaminergic denervation, but is early associated with altered [123I]FP-CIT binding 
in the caudate. Further, despite the efforts that were undertaken in standardising [123I]FP-CIT 
scans among the different PPMI centres, the method per se is interference-prone, especially 
in a multi-centre approach. We also did not take into consideration important confounding 
factors such as comorbidities and non-dopaminergic medication, as well as the fact that PD 
patients with EDS exhibited a more severe disease from several perspectives. Therefore, the 
pathophysiological causality of caudate denervation to EDS is disputable. 
It is important to note, however, that we explored the potential covariating nature of reduced 
caudate [123I]FP-CIT by investigating extrastriatal morphological changes. As well as finding 
no structural differences between PD patients with EDS compared to those without, cortical 
and subcortical alterations did not predict the manifestation of EDS, even at the univariate 
level. This highlights that extrastriatal degeneration may not be a causal factor underlying 
EDS within early-stage PD patients. Further, our results indicate that the loss of DAT within 
the caudate does not reflect the loss of neurons, therefore suggesting that early functional 
and/or molecular changes in PD may be contributing to the pathology of EDS. We were, 
however, unable to explore the structural integrity of the hypothalamus, thus cannot exclude 
its potential contribution to EDS.   
The lack of association found between EDS and levodopa or dopamine agonists may be due 
to the inaccuracies in recording the initiation of medication. Participants could start dopamine 
replacement therapy, at any point following their baseline visit, as part of their routine 
clinical care. Unfortunately, information regarding the medication dosage is not clearly 
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reported within the PPMI database, highlighting that the lack of correlation found between 
EDS development and dopamine replacement therapy is difficult to support.   
Despite the uncertainty revolving around the causality, the presence of caudate impairment at 
the time of PD diagnosis can aid the identification of a sub-population at higher risk to 
develop EDS. This sub-population of PD patients might be included in clinical trials 
specifically designed to tackle their patterns of non-motor symptoms, which, although 
significantly impair quality of life, are poorly recognised and inadequately treated [5]. 
Clinical experience has revealed that many non-motor symptoms, including dysautonomia 
and cognitive deficits, do not respond to dopaminergic treatment, though EDS is exacerbated 
by dopamine agonists. It is, therefore, fundamental to distinguish symptoms with a potential 
non-dopaminergic basis in order to make the correct choice of treatment. Delving deeper into 
the aetiology and mechanisms underlying non-motor symptoms will open avenues for the 
development of novel, effective drugs.  
 
Simuni et al. [45] also explored the correlates of EDS, as defined by the Epworth Sleepiness 
Scale, in a cohort of early stage, de novo PD patients, which instigated us to determine 
whether a different measure of EDS arrives to similar conclusions. Simuni and colleagues 
similarly discovered associations between EDS and UPDRS Part-I and –II, autonomic 
dysfunction and depression [33]. However, they were unable to find an association between 
EDS and caudate [123I]FP-CIT uptake or cognitive performance, as well as no difference in 
EDS prevalence between PD subjects and healthy controls. This could cast some doubt on 
whether the reported findings in this paper and the Simuni paper have any relevance to PD in 
particular. Given the de novo nature of the PD patients and their short disease durations, it 
could be possible that the correlations found may not be specific to Parkinson’s disease per 
se, but the general population suffering from EDS. In this direction, EDS in early PD may be 
driven by factors unrelated to PD-specific pathology. Therefore, caudate denervation in EDS-
positive PD patients, specifically, may simply pose as an indicator of other neural systems 
participating in the initiation and maintenance of sleep and alertness, which are affected in 
those suffering from daytime sleepiness, regardless of whether they are diagnosed with PD or 
not. Having said this, however, EDS is more frequent in treated patients, suggesting that 
either the progression of the disease and/or treatment may be critical in the development of 
this symptom, highlighting that, although there may not be differences in the prevalence of 
EDS within early PD compared to healthy controls, PD pathophysiology may propel this 
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multifaceted phenomenon, thus its relationship with other non-motor symptoms and cognitive 
impairment.  
 
Understanding the pathophysiology of NMS, including determining which systems are 
involved, will encourage the development of therapies that can tackle the multicentric nature 
of PD, hence alleviate debilitating symptoms, including EDS. Though we found an 
association between EDS and caudate denervation, the pathophysiological causality is 
debateable. Therefore, impairment of dopaminergic function within the caudate should be 
further investigated to confirm its role in regulating the sleep-wake cycle.  
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Figure 1. [123I]FP-CIT images showing basal ganglia regions. PD patients with EDS had a 
significant reduction in [123I]FP-CIT binding in the caudate compared to PD patients without 
EDS. (A) A 65-year old male PD patient without EDS (B) A 69-year old female PD patient with EDS  
EDS = Excessive daytime sleepiness. 
 
Figure 2. Comparison between Parkinson’s disease patients with EDS and without EDS.  
(A) Bar column graphs showing PD patients with EDS have significantly reduced caudate [123I]FP-CIT 
binding (P=0.025), higher burden of non-motor symptoms (MDS-UPDRS Part I and –II, P<0.001; 
P=0.001, respectively), have worse autonomic dysfunction (SCOPA-AUT, P<0.001), are more 
depressed (GDS, P=0.002), and are more cognitively impaired (MoCA, P=0.01). (B) Caudate [123I]FP-
CIT binding (r=-0.192; P=0.013), global non-motor symptom burden (MDS-UPDRS Part I, ρ=0.470; 
P<0.001) worse motor experiences of daily living (MDS-UPDRS Part II, ρ=0.349; P<0.001), 
autonomic dysfunction (SCOPA-AUT, ρ=0.366; P>0.001,), depression (ρ=0.264; GDS, P=0.002) and 
cognitive impairment (MoCA, ρ=-0.175; P=0.024,) all correlate with a higher degree of EDS.  
EDS = Excessive daytime sleepiness. 
 
 
Figure 3.Kaplan–Meier overall survival curve for the development of EDS in the population of 
PD patients without EDS.  EDS were higher for patients with abnormal caudate [123I]FP-CIT (<1.75). 
Patients with abnormal caudate [123I]FP-CIT had a 1.94 fold increase risk of EDS compared to those 
with normal caudate values (P=0.030). 
EDS = Excessive daytime sleepiness 
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Table 1. Demographic and clinical characteristics for 84 PD patients with and without EDS 
 
 PD-EDS- 
(n=84) 
PD-EDS+ 
(n=84) 
P value* 
 
Cohen’s d Effect size 
Demographic characteristics 
Age at screening, 
mean ±SD 
64.90 ±8.86 64.91 ±8.73 0.996  - - 
Gender male, % (n) 
 
66.70 (56) 70.20 (59) 0.621 - - 
Age at diagnosis, 
mean ±SD 
64.26 ±8.84 64.25 ±8.68 0.991 - - 
PD duration (months), 
mean ±SD 
7.65 ±7.36 7.99 ±7.18 0.767 - - 
Family history of PD, 
% (n) 
27.40 (23) 23.80 (20) 0.598 - - 
Year of Education, 
mean ± SD 
16.21 ±3.19 15.98 ±2.39 0.584 - - 
Motor and non-motor features  
H&Y stage, mean ± 
SD 
1.60 ±0.49 1.74 ±0.49 0.063 0.286 0.141 
MDS-UPDRS Part I, 
mean ±SD 
4.10 ±2.97 9.07 ±4.03 P<0.001 1.404 0.575 
MDS-UPDRS Part II, 
mean ±SD 
5.44 ±4.07 7.83 ±4.74 0.001 0.541 0.261 
MDS-UPDRS Part III 
in OFF, mean ±SD 
21.13 ±9.25 24.00 ±8.96 0.036 0.315 0.156 
MDS-UPDRS Total, 
mean ±SD 
30.67 ±12.67 40.90 ±13.08 P<0.001 0.794 0.369 
Bradykinesia 
subscore, mean ±SD 
10.98 ±5.79 11.95 ±6.06 0.287 0.164 0.082 
Postural instability 
subscore, mean ±SD 
1.36 ±1.07 1.35 ±1.79 0.024 0.007 0.003 
Rigidity subscore, 
mean ±SD 
3.75 ±2.51 4.45 ±2.79 0.088 0.264 0.131 
Tremor subscore, 
mean ±SD 
1.49 ±1.15 1.18 ±1.51 0.894 -0.231 -0.115 
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SCOPA-AUT, mean ± 
SD 
8.74 ±5.56 11.96 ±5.99 P<0.001 0.557 0.268 
GDS, mean ±SD 
 
1.77 ±1.90 2.54 ±2.55 0.002 0.342 0.169 
STAI Total Score, 
mean ±SD 
61.55 ±16.63 65.69 ±19.01 0.135 0.232 0.115 
MoCA, mean ±SD 
 
27.42 ±2.14 26.50 ±2.38 0.010 -0.407 -0.199 
BJLOS, mean ±SD 
 
12.68 ±2.31 12.81 ±2.13 0.703 0.059 0.029 
HVLT Total, mean 
±SD 
36.51 ±5.67 35.92 ±5.53 0.492 -0.105 -0.053 
SFT Score, mean ±SD 48.95 ±11.38 45.73 ±10.11 0.054 -0.299 -0.148 
SDMT Score, mean 
±SD 
41.10 ±9.72 39.06 ±9.69 0.176 -0.210 -0.105 
UPSIT, mean ± SD 21.40 ±8.31 20.63 ±7.51 0.527 -0.097 -0.049 
ADL, mean ± SD 
 
93.49 ±5.96 91.79 ±5.84 0.063 -0.288 -0.143 
 [123I]FP-CIT imaging  
Caudate, mean ±SD 
 
2.06 ±0.53 1.87 ±0.54 0.025 -0.355 -0.175 
Putamen, mean ±SD 
 
0.83 ±0.27 0.77 ±0.30 0.164 -0.210 -0.105 
Striatum, mean ±SD 
 
1.45 ±0.38 1.32 ±0.39 0.038 -0.338 -0.166 
SCOPA-AUT: the scale for outcomes for PD-autonomic function; GDS: 15-item Geriatric Depression 
Scale, MoCA: Montreal Cognitive Assessment Scale; BJLOS: Benton Judgement of Line Orientation; 
HVLT: Hopkins Verbal learning Test – revised; STAI: state and train anxiety scale 
*P values are Bonferroni corrected 
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Highlights 
 Excessive daytime sleepiness is associated with reduced caudate [123I]FP-CIT uptake  
 The severity of sleepiness correlates with decreased [123I]FP-CIT uptake in the caudate 
 Abnormal caudate [123I]FP-CIT uptake and disease duration predict the development of 
sleepiness  
 Daytime sleepiness is associated with neuropsychiatric and non-motor symptom burden 
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